Salarius' Seclidemstat Shows Single-Agent Drug Activity in Heavily Pre-Treated Sarcomas Patients

Salarius Pharmaceuticals Inc SLRX presented data at the American Society of Clinical Oncology Virtual Annual Meeting for seclidemstat, a reversible inhibitor of the lysine-specific histone demethylase 1 (LSD1), an enzyme that plays a key role in the development and progression of several cancers.
Data demonstrated that seclidemstat has a manageable safety profile, favorable pharmacokinetics that supports twice-daily (BID) oral dosing.
It showed evidence of anti-tumor activity in an advanced, heavily pre-treated patient population, as well as no significant hematological toxicities.
Single-agent seclidemstat treatment showed signs of drug activity in patients with relapsed/refractory Ewing sarcoma and other advanced cancers, including FET-rearranged sarcomas.
In patients with FET-rearranged sarcomas, seclidemstat treatment resulted in stable disease (SD) and prolonged time to progression (TTP) suggestive of disease control, a clinically relevant endpoint for soft tissue sarcomas.
In relapsed/refractory Ewing sarcoma population, a patient dosed at 600 mg BID achieved a reduction in three target lesions after 58 days (two cycles) with further tumor shrinkage after 112 days (four cycles) and 168 days (six cycles) for a maximum 76% tumor shrinkage despite the overall progressive disease.
Two additional patients dosed at 600 mg BID and 900 mg BID for 56 days (two cycles) demonstrated overall stable disease.
In another solid tumor study, seven patients treated for ovarian cancer, prostate cancer, and sarcomas achieved SD after two cycles with a median TTP of 4.3 months.
3 FET-rearranged sarcoma patients demonstrated TTP of 9.4 months, 7.2 months, and 4.3 months, respectively.
Price Action: SLRX shares are up 0.83% at $1.22 during the market session on the last check Monday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga